MacPherson, Laura
Anokye, Juliana
Yeung, Miriam M.
Lam, Enid Y. N.
Chan, Yih-Chih
Weng, Chen-Fang
Yeh, Paul
Knezevic, Kathy
Butler, Miriam S.
Hoegl, Annabelle
Chan, Kah-Lok
Burr, Marian L.
Gearing, Linden J.
Willson, Tracy
Liu, Joy
Choi, Jarny
Yang, Yuqing
Bilardi, Rebecca A.
Falk, Hendrik
Nguyen, Nghi
Stupple, Paul A.
Peat, Thomas S.
Zhang, Ming
de Silva, Melanie
Carrasco-Pozo, Catalina
Avery, Vicky M.
Khoo, Poh Sim
Dolezal, Olan
Dennis, Matthew L.
Nuttall, Stewart
Surjadi, Regina
Newman, Janet
Ren, Bin
Leaver, David J.
Sun, Yuxin
Baell, Jonathan B.
Dovey, Oliver
Vassiliou, George S.
Grebien, Florian
Dawson, Sarah-Jane
Street, Ian P.
Monahan, Brendon J.
Burns, Christopher J.
Choudhary, Chunaram
Blewitt, Marnie E.
Voss, Anne K.
Thomas, Tim
Dawson, Mark A.
Article History
Received: 5 September 2018
Accepted: 12 November 2019
First Online: 11 December 2019
Competing interests
: M.A.D. has been a member of advisory boards for CTX CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. The Dawson, Thomas and Voss laboratories receive research funding from CTx CRC. The remaining authors declare no competing financial interests.